Incubated companies are in healthcare.
Showing 245 of 245 companies
89bio was acquired by Roche in September 2025.
Aiolos was acquired by GSK in January 2024.
Ajax was acquired by Eli Lilly in April 2026.
Aliada Therapeutics was incubated by Raven and was acquired by AbbVie in October 2024.
Apogee Therapeutics was acquired by AbbVie in June 2026.
Audentes was acquired by Astellas in January 2020.
Avexis was acquired by Novartis in April 2018.
Biohaven develops treatments for immunology, neuroscience, and oncology diseases.
Bluejay Therapeutics was acquired by Mirum Pharmaceuticals in January 2026.
Calimmune was acquired by CSL in August 2017.
cAMPfield develops oral medicines for immune-mediated inflammatory diseases like IBD.
Capstan was acquired by AbbVie in June 2025.
Carmot Therapeutics was acquired by Roche in December 2023.
Cellcentric develops small molecule inhibitors for multiple myeloma and other cancers.
Century develops iPSC-derived cell therapies for cancer and autoimmune diseases.
Cidara Therapeutics was acqiured by Merck & Co. in November 2025.
Claris Bio is an ophthalmology company developing drugs to treat corneal diseases.
Clementia Pharma was acquired by Ipsen in February 2019.
Connect Biopharma develops immune modulators for asthma and COPD.
Contraline develops hormonal and non-hormonal male contraceptives.
Conveyor’s develops ADCs to deliver immunosuppressive payloads.
Crinetics Therapeutics was acquired by Vertex Pharmaceuticals in July 2026.
Curevo Vaccine, Inc. was acquired by Eli Lilly in May 2026.
Cytek is leading cell analysis solutions company.
Day One was acquired by Servier in March 2026.
DICE Therapeutics was acquired by Eli Lilly in June 2023.
Dicerna Pharmaceuticals was acquired by Novo Nordisk in November 2021.
Dimension Therapeutics was acquired by Ultragenyx in October 2017.
DTx Pharma was acquired by Novartis in July 2023.
Eidos was acquired by BridgeBio in October 2020.
Elektrofi was acquired by Halozyme in November 2025.
Element develops disruptive DNA sequencing for research and diagnostics.
Emergence Therapeuticsis was acquired by Eli Lilly in June 2023.
Familiar Machines & Magic is pioneering Consumer Physical AI.
Forge Biologics was acquired by Ajinomoto in November 2023.
Forma was acquired by Novo Nordisk in September 2022.
G1 Therapeutics was acquired by PharmaCosmos in September 2024.
Galera Therapeutics was acquired by Obsidian Therapeutics in April 2026.
GIVAX is developing a dual rotavirus/norovirus vaccine.
Global Blood Therapeutics was acquired by Pfizer in August 2022.
Halda was acquired by J&J in November 2025.
HilleVax was acquired by Xoma Royalty in August 2025.
Icosavax was acquired by AstraZeneca in December 2023.
IDRX was acquired by GSK in January 2025.
Imara was acquired by Enliven Therapeutics in February 2023.
Inhibrx Inc was acquired by Sanofi in January 2024.
Inozyme was acquired by BioMarin in May 2025.
Interius Biotherapeutics was acquired by Kite Pharma (Gilead) in August 2025.
IO Biotech develops cancer vaccines.
Ivantis was acquired by Alcon in November 2021.
Jnana was acquired by Otsuka Pharmaceutical in August 2024.
Juno was acquired by Celgene in January 2018.
KalVista Pharmaceuticals was acquired by the Chiesi Group.
Kinnate was acquired by Xoma Royalty in February 2024.
LENZ Therapeutics commercializes VIZZ® for the treatment of presbyopia.
Lumena Pharmaceuticals was acquired by Shire in May 2014.
Magenta’s devices treat heart failure through fluid removal and kidney protection.
Mariana was incubated by Raven and was acquired by Novartis in May 2024.
Memento is advancing novel antibody therapies for patients with retinal diseases.
Merus was acquired by Genmab in September 2025.
Metsera was acquired by Pfizer in September 2025.
Natera provides molecular and bioinformatics tests.
Nimbus is a structure-based drug discovery company.
Nivalis was acquired by Alpine Immune Sciences in April 2017.
Developing inhaled broad-spectrum antiviral therapies for respiratory infections.
Olema Oncology is developing targeted therapies for women’s cancers.
Ollin’s biologic for retinal diseases blocks two disease pathways with one molecule.
Orchard was acquired by Kyowa Kirin in October 2023.
Outpace Bio designs AI-enabled T‑cell therapies for solid tumors.
Pahr develops novel therapies for pulmonary arterial hypertension.
Pandion was acquired by Merck in February 2021.
Peloton Therapeutics was acquired by Merck in May 2019.
Phathom Pharmaceuticals commercializes and develops treatments for GI diseases.
Pinnacle develops oral peptide therapeutics with the convenience of oral dosing.
POINT Biopharma was acquired by Eli Lilly in October 2023.
Poplar develops anti-IgE antibodies food allergy, asthma, and atopic dermatitis.
Prevail was acquired by Eli Lilly in December 2020.
ProfoundBio was acquired by Genmab in April 2024.
Protagonist Therapeutics develops peptide therapeutics.
Ra Pharmaceuticals was acquired by UCB in April 2020.
Satsuma Pharmaceuticals was acquired by Shin Nippon Biomedical Labs in April 2023.
Secretome develops novel therapies derived from neonatal cardiac progenitor cells.
Serapha is a clinical-stage biotech developing a novel base editing therapy for AATD.
Seres Therapeutics develops microbiome drugs.
Shockwave was acquired by J&J in May 2024.
Sidera develops cardiometabolic therapies informed by human genetics.
Sierra Oncology was acquired by GSK in April 2022.
Silverback reverse merged with ARS Pharma in 2022.
Planetary health company currently in stealth.
Stipple targets tumor-specific cell surface proteins for precision oncology medicines.
Synolo develops TCEs for autoimmune diseases and oncology.
Synthorx was acquired by Sanofi in December 2019.
T‑Knife develops T‑cell therapies for solid tumors.
TARIS Biomedical was acquired by J&J in December 2019.
Selective AKT1-inhibitors for advanced cancer and rare genetic vascular disorders.
Terrestrial’s microneedle patch enables precise, controlled delivery of GLP-1s.
Typewriter is developing a gene writing system to cure genetic diseases.
Ventus develops small molecules for autoimmune, inflammatory, and neuro disorders.
Verdiva Bio develops oral GLP‑1 therapies for obesity and cardiometabolic disorders.
Verve was acquired by Eli Lilly in June 2025.
ViaCyte was acquired by Vertex in July 2022.
Vividion was acquired by Bayer in August 2021.
Vor Bio is developing telitacicept to address serious autoantibody-driven conditions.
Werewolf develops cytokine-based immunotherapies for oncology indications.
Transforming treatment for people living with serious immunological conditions.
